Establishment nasopharyngeal carcinoma organoid llibrary and individualized precision treatment of nasopharyngeal carcinoma

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1900024322

Enrollment

Unknown

Registered

2019-07-06

Start date

2019-09-30

Completion date

Unknown

Last updated

2019-07-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

nasopharyngeal carcinoma

Interventions

experimental group:new antineoplastic drug

control group:cisplatin

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Diagnosed with nasopharyngeal carcinoma by pathology; 2. Without serious heart and lung and other organ diseases; 3. Sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Happened with serious adverse drug reactions; 2. Failed the follow-up or midway exit. 3. Terminate in other unpredictable situations.

Design outcomes

Primary

Measure	Time frame
ki67;SOX2;Genes that are highly expressed in nasopharyngeal carcinoma;	—

Countries

China

Contacts

Public ContactYiqun Yu

Eye, Ear, Nose & Throat Hospital of Fudan University

yu_yiqun@fudan.edu.cn+86 13651673570

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026